Silent and non-silent thromboembolic events after ventricular tachycardia ablation: Modifiable risk with postprocedure anticoagulation?
Administration, Oral
Anticoagulants
/ administration & dosage
Asymptomatic Diseases
Catheter Ablation
/ adverse effects
Clinical Decision-Making
Drug Administration Schedule
Humans
Practice Patterns, Physicians'
Risk Factors
Tachycardia, Ventricular
/ diagnosis
Thromboembolism
/ diagnosis
Treatment Outcome
anticoagulation
catheter ablation
stroke
thromboembolism
ventricular tachycardia
Journal
Journal of cardiovascular electrophysiology
ISSN: 1540-8167
Titre abrégé: J Cardiovasc Electrophysiol
Pays: United States
ID NLM: 9010756
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
30
05
2019
revised:
18
06
2019
accepted:
25
06
2019
pubmed:
2
7
2019
medline:
29
9
2020
entrez:
2
7
2019
Statut:
ppublish
Résumé
There is increasing recognition of silent and clinically apparent thromboembolic events after left-sided ventricular tachycardia (VT) ablation. However, unlike atrial fibrillation ablation procedures where postablation oral anticoagulation (OAC) is universal, there is significant practice variation in OAC use after VT ablation. Herein, we review the data on post-VT ablation thromboembolism and evidence on the use of OAC, we suggest that OAC merits consideration in most cases after a balanced assessment of risks and benefits in individual patients, and we discuss future directions.
Substances chimiques
Anticoagulants
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1197-1199Informations de copyright
© 2019 Wiley Periodicals, Inc.